Login to Your Account



Alnylam's RSV Therapy in Limbo After Phase IIb Miss

By Catherine Shaffer
Staff Writer

Thursday, May 31, 2012
The future of Alnylam Pharmaceuticals Inc.'s RNAi candidate for respiratory syncytial virus (RSV), ALN-RSV01, could be either continued development or total termination, according to CEO John Maraganore, following the drug's failure to hit its primary endpoint in a Phase IIb trial against progressive bronchiolitis obliterans syndrome (BOS) in lung transplant patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription